News

bit.bio launches the first commercially available human iPSC-derived disease models for Parkinson’s disease that carry the PRKN R2...

The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.

Offering will provide robust, standardised tools for research and drug discovery.

Mark Kotter shares his thoughts in Labiotech on the importance of government support in enabling the UK to become a leading scienc...

bit.bio launches early access to ioSensory Neurons for chronic pain research and therapeutics development for peripheral neuropath...

Weslie Janeway - investor, philanthropist, and scientist - joins bit.bio's Board of Directors.

This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...

Our CEO and host Jim Cornall have a wide ranging discussion around cell programming, the ethics and use of human cells in research...